New Page 14

The Lyme criminals could not even read their Western Blots in LYMErix or ImmuLyme-vaccinated people, yet they claimed to have used the Dearborn Method to assess their vaccines outcomes:

Here are those 4 "we can't read our OspA vaccine results" reports:
1) SCHOEN and PERSING, with JOHN ANDERSON,1996:
http://jcm.asm.org/cgi/reprint/35/1/233?view=long&pmid=8968914
2) SCHOEN AND PERSING IN THEIR 1996 RICO METHOD PATENT:
The Dave Persing, Mayo Clinic FRAUD Patent-6,045,804
3) PERSING WITH SIGAL EXPLAINING THAT THE WESTERN BLOTS WERE UNREADABLE, 2000:
http://www.journals.uchicago.edu/doi/pdf/10.1086/313920
4) Yale's ROBERT SCHOEN in the 1998 Munchausen's Book, instructing MDs to blow off LYMErix systemically injured people ("but send the post-vaccination blood to the Yale L2 Diagnostics RICO lab if you must bother to be a physician").

This is a FALSE CLAIM or a QUI TAM or FRAUD on the GOVERNMENT

The 1998 Vaccines Reports (ImmuLyme and LYMErix):

LYMErix results (76% "safe and effective"):
http://content.nejm.org/cgi/content/abstract/339/4/209

ImmuLyme results (92% "safe and effective"):
http://content.nejm.org/cgi/content/abstract/339/4/216

From the LYMErix trial, "categories of outcomes:"
http://content.nejm.org/cgi/content-nw/full/339/4/209/T1

Knowing they had no proof LYMErix or ImmuLyme prevented Lyme Disease, they proceeded to use it against Czech children, when there's not even any of that kind of OspA in Europe.

I hope Czechoslovakia sues Corrupticut and Yale. UCONN/Yale/SmithKline experimented on children with a vaccine that would do no good in Europe just to see how much damage the vaccine would do. They also knew LYMErix did not prevent Lyme in the US.

Antibody responses to the three genomic groups of Borrelia burgdorferi in European Lyme borreliosis.

Division of Rheumatology/Immunology, New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts 02111.

The antibody responses to the three genomic groups of Borrelia burgdorferi (B. burgdorferi sensu stricto, Borrelia garinii, and Borrelia afzelii) were determined in 97 German patients with various manifestations of Lyme borreliosis. The geometric mean antibody titers in each patient group, determined by ELISA, were similar with each antigen preparation. By Western blotting, however, patients with meningopolyneuritis tended to respond to more spirochetal polypeptides of B. garinii, the group 2 strain, whereas those with arthritis recognized more antigens of B. afzelii, the group 3 strain (P < .03), as did those with acrodermatitis. Only 1 patient each with erythema migrans, arthritis, or acrodermatitis had weak reactivity with outer surface protein A (OspA), and none responded to OspB. It is concluded that differences among the three groups of B. burgdorferi may result in variations in the antibody response in European Lyme borreliosis. PMID: 8106763 [PubMed - indexed for MEDLINE]

Immunogenicity of a recombinant Borrelia burgdorferi outer surface protein A vaccine against Lyme disease in children.

Department of Family Medicine, University of Connecticut Health Center, Farmington, Connecticut 06030-1406, USA.

BACKGROUND AND OBJECTIVE: A recombinant lipoprotein vaccine against Lyme disease, containing 30 microg of Borrelia burgdorferi outer surface protein A (OspA) with aluminum adjuvant, has been shown in a large US field trial of subjects >/=15 years of age to offer 76% efficacy against clinical Lyme disease after 3 injections given at 0, 1, and 12 months. Lyme disease is also an important problem in children; thus, OspA vaccine trials in children are needed. The purpose of this study was to investigate the safety and immunogenicity of 2 different doses of lipoprotein OspA with aluminum adjuvant vaccine in healthy children 5 to 15 years of age in a double-blind, randomized study. STUDY DESIGN: In a double-blind study, 250 children from the Czech Republic were randomly assigned to receive 15 microg or 30 microg of OspA vaccine at 0, 1, and 2 months. Serum samples, obtained before vaccination and 1 month after the second and third doses, were analyzed for antiOspA antibody. Solicited and unsolicited symptoms were collected from diary cards. RESULTS: Local pain at the injection site was reported by approximately 76% of the 250 children. Headaches (after 5% to 18% of the injections) and malaise (after 2% to 16% of the injections) were the most frequently reported general symptoms. Local and generalized symptoms were not different between the 15 microg and 30 microg groups, and all symptoms resolved within 4 days. Both doses were highly immunogenic, with the 30 microg dose eliciting higher antibody levels. Seroconversion occurred in 99% of the 250 children. CONCLUSIONS: The OspA vaccine against Lyme disease was well tolerated and highly immunogenic in children. PMID: 10547245 [PubMed - indexed for MEDLINE]